Solasia Pharma KK (JP:4597)
:4597
Want to see JP:4597 full AI Analyst Report?
Top Page
Solasia Pharma KK
(4597)
Select Model
Select Model
Rating:42Neutral
Price Target:
¥21.00
▼(-22.22% Downside)
Action:Reiterated
Date:05/17/26
The score is held down primarily by persistent operating losses and significant negative operating/free cash flow, despite low balance-sheet leverage. Technical indicators also lean bearish with the stock trading below key moving averages and a negative MACD, while valuation metrics are inconclusive due to a negative P/E and no dividend yield provided.
Positive Factors
Specialty oncology and supportive-care focus
A focused specialty oncology/supportive-care business targets persistent unmet clinical needs and hospital channels. This niche model supports repeatable demand, easier partner alignment for commercialization, and durable revenue opportunities from medicines used alongside cancer treatments.
Negative Factors
Persistent operating losses
Ongoing sizable operating losses constrain internal reinvestment and make the company reliant on external funding or milestone payments. Persistent losses also limit ability to execute independently and increase dilution or partner-dependence risk over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialty oncology and supportive-care focus
A focused specialty oncology/supportive-care business targets persistent unmet clinical needs and hospital channels. This niche model supports repeatable demand, easier partner alignment for commercialization, and durable revenue opportunities from medicines used alongside cancer treatments.
Read all positive factors
Solasia Pharma KK (4597) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.01B
Dividend YieldN/A
Average Volume (3M)41.98M
Price to Earnings (P/E)―
Beta (1Y)0.94
Revenue Growth24.62%
EPS Growth60.41%
CountryJP
Employees23
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-3.53
Shares Outstanding273,414,370
10 Day Avg. Volume52,616,870
30 Day Avg. Volume41,982,023
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)3.93
Price to Sales (P/S)16.06
P/FCF Ratio-8.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2
Revenue Forecast (FY)¥1.92B
Solasia Pharma KK Business Overview & Revenue Model
Company Description
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil...
How the Company Makes Money
Solasia Pharma makes money primarily through commercialization and partnering of its pharmaceutical products. Key revenue streams typically include (1) product sales in markets where it directly commercializes approved drugs (recorded as net sales...
Solasia Pharma KK Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
70
Positive
Cash Flow
8
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 410.00M | 429.00M | 316.00M | 617.00M | 1.09B | 559.00M |
| Gross Profit | 170.00M | 171.00M | -10.00M | -163.00M | 128.00M | -121.00M |
| EBITDA | -831.00M | -822.00M | -796.00M | -639.00M | -1.20B | -1.92B |
| Net Income | -891.00M | -876.00M | -1.94B | -1.11B | -2.55B | -2.48B |
Balance Sheet | ||||||
| Total Assets | 1.99B | 2.15B | 1.36B | 2.55B | 3.56B | 3.76B |
| Cash, Cash Equivalents and Short-Term Investments | 1.57B | 1.39B | 886.00M | 728.00M | 803.00M | 714.00M |
| Total Debt | 86.00M | 159.00M | 25.00M | 60.00M | 37.00M | 84.00M |
| Total Liabilities | 281.00M | 392.00M | 203.00M | 673.00M | 899.00M | 1.17B |
| Stockholders Equity | 1.71B | 1.75B | 1.16B | 1.88B | 2.66B | 2.59B |
Cash Flow | ||||||
| Free Cash Flow | -1.12B | -847.00M | -1.03B | -359.00M | -2.07B | -2.48B |
| Operating Cash Flow | -1.12B | -847.00M | -1.03B | -359.00M | -2.07B | -2.47B |
| Investing Cash Flow | -97.00M | -81.00M | 0.00 | 2.00M | -418.00M | -164.00M |
| Financing Cash Flow | 1.68B | 1.43B | 1.18B | 275.00M | 2.57B | 361.00M |
Solasia Pharma KK Technical Analysis
Negative
27.00
Price Trends
30.30
Negative
30.66
Negative
32.24
Negative
Market Momentum
-2.31
Positive
31.78
Neutral
22.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4597, the sentiment is Negative. The current price of 27 is above the 20-day moving average (MA) of 24.85, below the 50-day MA of 30.30, and below the 200-day MA of 32.24, indicating a bearish trend. The MACD of -2.31 indicates Positive momentum. The RSI at 31.78 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4597.
Solasia Pharma KK Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥12.72B | 23.72 | ― | ― | 1.62% | -25.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥5.61B | 27.79 | ― | 3.21% | 1.60% | -32.76% | |
48 Neutral | ¥5.45B | -6.47 | ― | ― | 246.42% | 9.39% | |
42 Neutral | ¥6.01B | -6.93 | -90.96% | ― | 24.62% | 60.41% | |
42 Neutral | ¥3.28B | -1.66 | ― | ― | ― | 14.26% | |
41 Neutral | ¥5.41B | -0.80 | ― | ― | -39.73% | -9.00% |
* Healthcare Sector Average
JP:4597
Solasia Pharma KK
23.00
-7.00
-23.33%
JP:4539
Nippon Chemiphar Co., Ltd.
1,528.00
90.87
6.32%
JP:4574
Taiko Pharmaceutical Co., Ltd.
253.00
5.00
2.02%
JP:4582
Symbio Pharmaceuticals Limited
70.00
-104.00
-59.77%
JP:4883
Modalis Therapeutics Corporation
34.00
-58.00
-63.04%
JP:4892
Cyfuse Biomedical K.K.
537.00
-376.00
-41.18%
Solasia Pharma KK Corporate Events
Solasia Pharma advances oncology pipeline, expands global reach for key cancer drugs
May 15, 2026
Solasia Pharma reported an update on its key pipeline alongside first-quarter results, highlighting a diversified oncology-focused portfolio and several external technology collaborations, including nucleic acid medicines, RNA-editing-based gene t...
Solasia Pharma Posts Wider Quarterly Loss and Withholds 2026 Guidance
May 15, 2026
Solasia Pharma reported consolidated sales of ¥6 million for the three months ended March 31, 2026, a 75.1% year-on-year decline, with an operating loss of ¥306 million and a net loss attributable to owners of the parent of ¥307 mil...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.